临床外科杂志 ›› 2025, Vol. 33 ›› Issue (10): 1091-1096.doi: 10.3969/j.issn.1005-6483.20241316

• 论著 • 上一篇    下一篇

微卫星不稳定及微卫星稳定右半结肠癌的生存分析

李俊川 刘华 温秀梅 钟小琼   

  1. 641300 四川资阳,资阳市雁江区人民医院胃肠外科
  • 收稿日期:2024-08-05 出版日期:2025-11-11 发布日期:2025-11-11
  • 基金资助:
    四川省医学科技创新研究会“医创圆梦”专项科研课题(2025YCYM041)

Survival analysis of microsatellite instability and microsatellite stable right-sided colon cancer

LI Junchuan,LIU Hua,WEN Xiumei,ZHONG Xiaoqiong   

  1. Gastrointestinal Surgery,People's Hospital of Yanjiang District,Ziyang City,Ziyang 641300,China
  • Received:2024-08-05 Online:2025-11-11 Published:2025-11-11

摘要: 目的 比较微卫星不稳定(dMMR)及微卫星稳定(pMMR)右半结肠癌的临床病理特征,分析两组总生存率(OS)及无病生存率(DFS)的影响因素。方法 2016年1月1日~2023年12月31日接受根治性切除术的右半结肠癌病人247例(dMMR 43例,pMMR 204例)。通过倾向性评分匹配,将两组基线资料有差异按1∶1进行匹配,共得到86例,dMMR和pMMR右半结肠癌各43例。分析两组间相关指标差异,并针对OS及DFS进行单因素和多因素的Cox分析。绘制生存曲线,生存率的比较采用Log-rank检验。结果 按年龄、部位、肿瘤最大长径、形态、组织学类型、T、N、TNM分期、神经受侵,分化程度(P<0.05)进行1∶1匹配,经匹配后,dMMR和pMMR右半结肠癌病人的基线资料比较,差异无统计学意义(P>0.05)。对OS及DFS研究后发现,dMMR右半结肠癌病人5年OS优于pMMR,dMMR右半结肠癌病人5年DFS优于pMMR,差异有统计学意义(P<0.05)。影响dMMR右半结肠癌OS的保护因素包括肿瘤最大长径<5cm、T1~3、M0、Ⅰ~Ⅲ期、无脉管内癌栓和无神经受侵(P<0.05)。生存分析中,M0对比M1分别为95%和60%,差异有统计学意义(P<0.05);Ⅰ~Ⅲ期对比Ⅳ期分别为95%和54%,差异有统计学意义(P<0.05);无脉管内癌栓对比有脉管内癌栓分别为94%和88%,差异有统计学意义(P<0.05)。影响dMMR右半结肠癌DFS的保护因素包括年龄<50岁、不含黏液成分或印戒细胞、M0、Ⅰ~Ⅲ期、无脉管内癌栓(P<0.05)。生存分析中,M0对比M1分别为90%和 63%,差异有统计学意义(P<0.05);Ⅰ~Ⅲ期对比Ⅳ期分别为92%和57%,差异有统计学意义P<0.05);无脉管内癌栓对比有脉管内癌栓分别为91%和77%,差异有统计学意义(P<0.05)。结论 dMMR右半结肠癌病人的OS及DFS高于pMMR,且不受临床因素的影响。

关键词: 结肠癌, 微卫星不稳定, 倾向性评分, 总生存率, 无病生存率

Abstract: Objective Compare the clinicopathological factors of microsatellite unstable(dMMR) and microsatellite stable(pMMR) in right colon cancer and analyze the factors affecting overall survival(OS) and disease-free survival(DFS) between the two groups.Methods Clinical data with right colon cancer of patients who underwent radical resection from January 1,2016 to December 31,2023 were retrospectively analyzed(a total of 247 patients were included,including 43 dMMR and 204 pMMR).Through propensity score matching,the baseline difference between the two groups was matched 1∶1,and a total of 86 cases were obtained,43 cases in dMMR and 43 cases in pMMR.The difference of relevant indicators between the two groups was analyzed,and univariate and multivariate Cox analysis was performed for OS and DFS.The survival curve was plotted, and the comparison of survival rates was conducted using the Log-rank test.Results According to age,location,tumor length,shape,histological type,T,N,TNM stage,nerve invasion,and differentiation degree with 1∶1 matching(P<0.05),there was no statistical difference in baseline data between dMMR and pMMR patients with right colon cancer(P>0.05).It was found that 5-year OS of dMMR patients with right colon cancer was significantly better than pMMR(P<0.05),and 5-year DFS dMMR was better than pMMR(P<0.05).Protective factors affecting OS of dMMR right colon cancer included tumor length<5cm,T1-3,M0,Stage Ⅰ-Ⅲ,absence of intravascular cancer thrombi and absence of nerve invasion(P<0.05).In survival analysis,M0 was compared with M1(95% vs. 60%,P<0.05).Stage Ⅰ-Ⅲ compared with stage Ⅳ(95% vs. 54%,P<0.05);No vascular cancer thrombus vs. cancer thrombus(94% vs.88%,P<0.05).Protective factors affecting DFS of dMMR right colon cancer included age < 50 years,no mucous or sig-ring cells,M0,Stage Ⅰ-Ⅲ,and no intravascular cancer thrombus(P<0.05).In survival analysis,M0 was compared with M1(90% vs. 63%,P<0.05).Stage Ⅰ-Ⅲ compared with stage Ⅳ(92% vs. 57%,P<0.05);There was a significant difference between non-vascular cancer thrombus and vascular cancer thrombus(91%vs. 77%,P<0.05).Conclusion The patients with dMMR had higher OS and DFS than pMMR,which were not affected by clinical factors.

Key words: colon cancer, microsatellite instability, propensity score, overall survival, disease-free survival

[1] 李淑萍 王璐 胡淑娜. 不同剂量瑞马唑仑全身麻醉诱导对结肠癌根治术病人气管插管应激反应及血流动力学的影响[J]. 临床外科杂志, 2025, 33(3): 306-309.
[2] 程逸风 张维康. 结直肠癌合并急性肠梗阻的治疗策略[J]. 临床外科杂志, 2024, 32(5): 457-460.
[3] 黄超 方兴刚 陈璐. 结肠癌病人血清miR-448和miR-153表达对肠道菌群及免疫功能的影响[J]. 临床外科杂志, 2024, 32(5): 506-510.
[4] 王少怡 聂凯 李冉冉 陈达丰 薛小军 叶磊 刘建平 周松. XELOX方案新辅助化疗治疗Ⅱ(T4)期、Ⅲ期结肠癌的疗效分析[J]. 临床外科杂志, 2024, 32(2): 188-191.
[5] 李阳 刘涛 曾立鹏 胡元祥 . 腹腔镜下右半结肠癌根治术后胃瘫综合征29例临床分析[J]. 临床外科杂志, 2024, 32(2): 196-198.
[6] 赵馨 尹健 贾彤. 纳布啡调节Hippo/YAP信号通路对结肠癌〖JP〗细胞增殖、凋亡和上皮间质转化的影响[J]. 临床外科杂志, 2024, 32(10): 1100-1104.
[7] 丁辉斌 周红飞. 经尾侧联合中线入路与中线入路在腹腔镜右半结肠癌D3根治术中的应用效果比较[J]. 临床外科杂志, 2023, 31(9): 869-872.
[8] 卢建利 贺伟 刘进衡. 基于倾向性评分匹配法评价三种方法治疗胆囊切除术后胆总管结石的疗效[J]. 临床外科杂志, 2023, 31(7): 635-639.
[9] 王健 钱群 吴云华. 结肠癌穿孔术后类白血病反应一例[J]. 临床外科杂志, 2023, 31(6): 579-580.
[10] 周硕 王振杰 孙万亮 张登勇 鲁正. 高龄结肠癌病人中CDH13的表达变化与临床及预后相关性研究[J]. 临床外科杂志, 2023, 31(2): 181-184.
[11] 马松鹤 罗建飞 赵晶. 尾内侧入路联合中间翻页式淋巴结清扫在腹腔镜右半结肠癌根治术中的临床应用[J]. 临床外科杂志, 2023, 31(12): 1176-1179.
[12] 姬生威 王萍. 微卫星不稳定性联合肿瘤突变负荷评估非小细胞肺癌病人术后复发转移的临床价值[J]. 临床外科杂志, 2023, 31(11): 1065-1067.
[13] 殷军锋 顾明. 沉默circ_0007385对结肠癌细胞增殖、迁移及凋亡的影响[J]. 临床外科杂志, 2022, 30(8): 762-766.
[14] 廖良功 胡俊杰 张弛 徐鹏飞 叶盛威 熊治国 . 原发性横结肠肝曲腺鳞癌一例[J]. 临床外科杂志, 2022, 30(8): 797-798.
[15] 刘珊 刘鑫 林友刚. GATA3/GATA6调控结肠癌细胞株自噬和增殖的机制[J]. 临床外科杂志, 2022, 30(7): 694-696.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!